3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Renal Cell
24
Kidney Neoplasms
8
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
von Hippel-Lindau Disease
4
Pheochromocytoma
2
Paraganglioma
2
Neoplasm Metastasis
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Recurrence
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neuroectodermal Tumors, Primitive
1
Neoplasms
1
Metastatic Castration-Resistant Prostate Cancer
1
Hemangioblastoma
1
Glioblastoma
1
Endometrial Neoplasms
1
Clear-cell metastatic renal cell carcinoma
1
Carcinoma
1
Breast Neoplasms
1
Adenoma, Islet Cell
1
Interventions
enzalutamide
7
Abiraterone Acetate
4
abiraterone
3
Prednisone
3
Docetaxel
3
sapanisertib
1
relugolix
1
pembrolizumab
1
onvansertib
1
olaparib
1
lenvatinib
1
inavolisib
1
belzutifan
1
apalutamide
1
abemaciclib
1
Prednisolone
1
PF06821497
1
Methylprednisolone
1
Lutetium-177
1
Lutetium
1
Gonadotropin-Releasing Hormone
1
Etoposide
1
Dexamethasone
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Metastatic Castration-Resistant Prostate Cancer
×
belzutifan
×
Clear all
NCT02861573
2026-02-17
KEYNOTE-365
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
1,200 enrolled